Effects of phlebotomy on the growth of ferric nitrilotriacetate-induced renal cell carcinoma

Acta Medica Okayama

Volumn 56, Issue 4, 2002, Pages 199-204

  Mizote, Akiko ^a   Hida, Akira I ^a   Hosako, Mutsumi ^a   Fujisawa, Masayoshi ^a   Kamekawa, Mika ^a   Okada, Shigeru ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Ferric nitrilotriacetate; Phlebotomy; Renal cell carcinoma

Indexed keywords

CARCINOGEN; DRUG DERIVATIVE; FERRIC ION; IRON; NITRILOTRIACETATE IRON; NITRILOTRIACETIC ACID;

ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; INCIDENCE; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; METABOLISM; PATHOLOGY; PHLEBOTOMY; RAT; WISTAR RAT;

ANIMALS; CARCINOGENS; CARCINOMA, RENAL CELL; FERRIC COMPOUNDS; INCIDENCE; IRON; KIDNEY NEOPLASMS; MALE; NITRILOTRIACETIC ACID; PHLEBOTOMY; RATS; RATS, WISTAR;

EID: 0036689559     PISSN: 0386300X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Okada S: Iron-induced tissue damage and cancer: The role of reactive oxygen species-free radicals. [Review] Pathol Int (1996) 46, 311-332.
2. Umemura T, Sai K, Takagi A, Hasegawa R and Kurokawa Y: Oxidative DNA damage, lipid peroxidation and nephrotoxicity induced in the rat kidney after ferric nitrilotriacetate administration. Cancer Lett (1990) 54, 95-100.
3. Toyokuni S, Tanaka T, Nishiyama Y, Okamoto K, Nakashima Y, Hamazaki S, Okada S and Hiai H: Induction of renal cell carcinoma in male Wistar rats treated with cupric nitrilotriacetate. Lab Invest (1996) 75, 239-248.
4. Yamaguchi R, Hirano T, Asami S, Sugita A and Kasai H: Increase in the 8-hydroxyguanine repair activity in the rat kidney after the administration of a renal carcinogen, ferric nitrilotriacetate. Environ Health Perspect (1996) 104 (Suppl 3), 651-653.
5. Zhang D, Okada S, Yu Y, Zheng P, Yamaguchi R and Kasai H: Vitamin E inhibits apoptosis, DNA modification, and cancer incidence induced by iron-mediated peroxidation in Wistar rat kidney. Cancer Res (1997) 57, 2410-2414.
6. Toyokuni S, Mori T, Hiai H and Dizdaroglu M: Treatment of Wistar rats with a renal carcinogen, ferric nitrilotriacetate, causes DNA-protein cross-linking between thymine and tyrosine in their renal chromatin. Int J Cancer (1995) 62, 309-313.
7. Hamazaki S, Okada S, Ebina Y, Li JL and Midorikawa O: Effect of dietary vitamin E on ferric nitrilotriacetate-induced nephrotoxicity in rats. Toxicol Appl Pharmacol (1988) 92, 500-506.
8. Toyokuni S, Okada S, Hamazaki S, Minamiyama Y, Yamada Y, Liang P, Fukunaga Y and Midorikawa O: Combined histochemical and biochemical analysis of sex hormone dependence of ferric nitrilotriacetate-induced renal lipid peroxidation in ddY mice. Cancer Res (1990) 50, 5574-5580.
9. Toyokuni S, Uchida K, Okamoto K, Hattori-Nakakuki Y, Hiai H and Stadtman ER: Formation of 4-hydroxy-2-nonenal-modified proteins in the renal proximal tubules of rats treated with a renal carcinogen, ferric nitrilotriacetate. Proc Natl Acad Sci USA (1994) 91, 2616-20.
10. Toyokuni S, Luo XP, Tanaka T, Uchida K, Hiai H and Lehotay DC: Induction of a wide range of C (2-12) aldehydes and C (7-12) acyloins in the kidney of Wistar rats after treatment with a renal carcinogen, ferric nitrilotriacetate. Free Rad Biol Med (1997) 22, 1019-1027.
11. Uchida K, Itakura K, Kawakishi S, Hiai H, Toyokuni S and Stadtman ER: Characterization of epitopes recognized by 4-hydroxy-2-nonenal specific antibodies. Arch Biochem Biophys (1995) 324, 241-248.
12. Kimoto T, Koya S, Hino K, Yamamoto Y, Nomura Y, Micallef MJ, Hanaya T, Aral S, Ikeda M and Kurimoto M: Renal carcinogenesis induced by ferric nitrilotriacetate in mice, and protection from it by Brazilian propolis and artepillin C. Pathol Int (2000) 50, 679-689.
13. Akiyama T, Hamazaki S and Okada S: Absence of ras mutations and low incidence of p53 mutations in renal cell carcinomas induced by ferric nitrilotriacetate. Jpn J Cancer Res (1995) 86, 1143-1149.
14. Nishiyama Y, Suwa H, Okamoto K, Fukumoto M, Hiai H and Toyokuni S: Low incidence of point mutations in H-, K-and N-ras oncogenes and p53 tumor suppressor gene in renal cell carcinoma and peritoneal mesothelioma of Wistar rats induced by ferric nitrilotriacetate. Jpn J Cancer Res (1995) 86, 1150-1158.
15. INK4A suppressor genes in oxystress-induced renal cell carcinoma of rats. Oncogene (1999) 18, 3793-3797.
16. Okada S: Iron and carcinogenesis in laboratory animals and humans: a mechanistic consideration and review of literature, Int J Clin Oncol (1998) 3, 191-203.
17. Awai M, Narasaki M, Yamanoi Y and Seno S: Induction of diabetes in animals by parenteral administration of ferric nitrilotriacetate. A model of experimental hemochromatosis. Am J Pathol (1979) 95, 663-673.
18. Brueckmann G and Zondek SG: An improved method for the determination of non-hem iron. J Biol Chem (1940) 135, 23-30.
19. Liu M, Okada S and Kawabata T: Radical-promoting "free" iron level in the serum of rats treated with ferric nitrilotriacetate: Comparison with other iron chelate complexes. Acta Med Okayama (1991) 45, 401-408.
20. Hamazaki S, Okada S, Toyokuni S and Midorikawa O: Thiobarbituric acid-reactive substance formation of rat kidney brush border membrane vesicles induced by ferric nitrilotriacetate. Arch Biochem Biophys (1989) 274, 348-354.
21. Okada S, Minamiyama Y, Hamazaki S, Toyokuni S and Sotomatsu A: Glutathione cycle dependency of ferric nitrilotriacetate-induced lipid peroxidation in mouse proximal renal tubules. Arch Biochem Biophys (1993) 301, 138-42.
22. Kawabata T, Ma Y-X, Yamadori I and Okada S: Iron-induced apoptosis in mouse renal proximal tubules after an injection of a renal carcinogen, iron-nitrilotriacetate. Carcinogenesis (1997) 18, 1389-1394.
23. Toyokuni S and Sagripanti JL: Induction of oxidative single-and double-strand breaks in DNA by ferric citrate. Free Radic Biol Med (1993) 15, 117-23.
24. Halliwell B and Aruoma OI: DNA and Free Radicals. Ellis Horwood, West Sussex (1993)
25. INK4A tumor suppressor gene after weeks of iron-mediated oxidative damage during rat renal carcinogenesis. Am J Pathol (2002) 160, 419-424.
26. Dreher D and Junod AF: Role of oxygen free radicals in cancer development. Eur J Cancer (1996) 32A, 30-38.
27. Kakehashi C, Mori M, Kawabata T and Okada S: In vitro transformation of rat renal cells by treatment with ferric nitrilotriacetate. Acta Med Okayama (2001) 55, 97-103.
28. Weinberg ED: Iron withholding: A defense against infection and neoplasia. Physiol Rev (1984) 64, 65-102.
29. Weinberg ED: Roles of iron in neoplasia. Promotion, prevention, and therapy. Biol Trace Elem Res (1992) 34, 123-140.
30. Hayashi H, Takikawa T, Nishimura N, Yano M, Isomura T and Sakamoto N: Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol (1994) 89, 986-988.
31. Kato J, Kobune M, Nakamura T, Kuroiwa G, Takada K, Takimoto R, Sato Y, Fujikawa K, Takahashi M, Takayama T, Ikeda T and Niitsu Y: Normalization of elevated hepatic 8-hydroxy-2′-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet. Cancer Res (2001) 61, 8697-8702.
32. Weinberg ED: The role of iron in cancer. Eur J Cancer Prev (1996) 5, 19-36.